Line 4: |
Line 4: |
| {{Under Construction}} | | {{Under Construction}} |
| | | |
− | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Light Chain and Heavy Chain Deposition Disease]]. | + | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-04. The original page can be found at [[HAEM4:Light Chain and Heavy Chain Deposition Disease]]. |
| }}</blockquote> | | }}</blockquote> |
| ==Primary Author(s)*== | | ==Primary Author(s)*== |
Line 14: |
Line 14: |
| ==Cancer Category / Type== | | ==Cancer Category / Type== |
| | | |
− | *[https://ccga.io/index.php/Mature_B-Cell_Neoplasms Mature B-cell neoplasms] | + | *[https://ccga.io/index.php/HAEM4:Mature_B-Cell_Neoplasms Mature B-cell neoplasms] |
| | | |
| ==Cancer Sub-Classification / Subtype== | | ==Cancer Sub-Classification / Subtype== |
| | | |
− | *[https://ccga.io/index.php/Monoclonal_Immunoglobulin_Deposition_Diseases Monoclonal immunoglobulin deposition disease] | + | *[https://ccga.io/index.php/HAEM4:Monoclonal_Immunoglobulin_Deposition_Diseases Monoclonal immunoglobulin deposition disease] |
| | | |
| ==Definition / Description of Disease== | | ==Definition / Description of Disease== |
Line 24: |
Line 24: |
| | | |
| *Systemic disorder with non-amyloid deposits of monoclonal immunoglobulin (Ig) in various organs | | *Systemic disorder with non-amyloid deposits of monoclonal immunoglobulin (Ig) in various organs |
− | *Underlying diseases are [[Plasma Cell Neoplasms]] (PCN, >95%) or lymphoplasmacytic neoplasms (2-3%) | + | *Underlying diseases are [[HAEM4:Plasma Cell Neoplasms]] (PCN, >95%) or lymphoplasmacytic neoplasms (2-3%) |
− | *20-35% have non-smoldering [[Plasma Cell Myeloma]] (PCM), and rest (65-75%) have smoldering plasma cell myeloma or Monoclonal Gammopathy of Uncertain Significance (MGUS)/monoclonal gammopathy of renal significance (MGRS) | + | *20-35% have non-smoldering [[HAEM5:Plasma cell myeloma / multiple myeloma]] (PCM), and rest (65-75%) have smoldering plasma cell myeloma or Monoclonal Gammopathy of Uncertain Significance (MGUS)/monoclonal gammopathy of renal significance (MGRS) |
| | | |
| ==Synonyms / Terminology== | | ==Synonyms / Terminology== |
Line 99: |
Line 99: |
| ==Morphologic Features== | | ==Morphologic Features== |
| | | |
− | *Most cases are associated with PCM or MGUS<ref name=":0" />, and rarely with [[Lymphoplasmacytic Lymphoma]], marginal zone lymphoma, or [[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]] | + | *Most cases are associated with PCM or MGUS<ref name=":0" />, and rarely with [[HAEM5:Lymphoplasmacytic lymphoma]], marginal zone lymphoma, or [[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma]] |
| *The smooth, ribbon-like linear Ig deposits consist of Congo red-negative amorphous eosinophilic material that is non-amyloid and non-fibrillary | | *The smooth, ribbon-like linear Ig deposits consist of Congo red-negative amorphous eosinophilic material that is non-amyloid and non-fibrillary |
| *Deposition of Ig is mostly found on renal biopsies but can be observed in bone marrow and other tissues | | *Deposition of Ig is mostly found on renal biopsies but can be observed in bone marrow and other tissues |
Line 124: |
Line 124: |
| | | |
| <blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the old template. Please incorporate above.}} | | <blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the old template. Please incorporate above.}} |
− | Findings are similar to those of the underlying condition (e.g., [[Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[Lymphoplasmacytic Lymphoma]]). Additional findings may include the following<ref name=":2" /><ref name=":4" />: | + | Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]). Additional findings may include the following<ref name=":2" /><ref name=":4" />: |
| | | |
| *The plasma cells in bone marrow may exhibit an aberrant kappa/lambda ratio | | *The plasma cells in bone marrow may exhibit an aberrant kappa/lambda ratio |
Line 224: |
Line 224: |
| <blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}} | | <blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}} |
| | | |
− | *Findings are similar to those of the underlying condition (e.g., [[Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[Lymphoplasmacytic Lymphoma]]) | + | *Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) |
| | | |
| </blockquote> | | </blockquote> |
Line 294: |
Line 294: |
| <blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}} | | <blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}} |
| | | |
− | *Findings are similar to those of the underlying condition (e.g., [[Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[Lymphoplasmacytic Lymphoma]]) | + | *Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) |
| | | |
| </blockquote> | | </blockquote> |
| ==Epigenomic Alterations== | | ==Epigenomic Alterations== |
| | | |
− | *Findings are similar to those of the underlying condition (e.g., [[Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[Lymphoplasmacytic Lymphoma]]) | + | *Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) |
| | | |
| ==Genes and Main Pathways Involved== | | ==Genes and Main Pathways Involved== |
Line 323: |
Line 323: |
| <blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}} | | <blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}} |
| | | |
− | *Findings are similar to those of the underlying condition (e.g., [[Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[Lymphoplasmacytic Lymphoma]]) | + | *Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) |
| | | |
| </blockquote> | | </blockquote> |
Line 349: |
Line 349: |
| ==Links== | | ==Links== |
| | | |
− | *[[Monoclonal Immunoglobulin Deposition Diseases]] | + | *[[HAEM4:Monoclonal Immunoglobulin Deposition Diseases]] |
− | *[[Primary Amyloidosis]] | + | *[[HAEM5:Immunoglobulin-related (AL) amyloidosis]] |
− | *[[Plasma Cell Myeloma|Plasma Cell Myeloma]] | + | *[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma Cell Myeloma]] |
− | *[[Non-IgM Monoclonal Gammopathy of Undetermined Significance]] | + | *[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance]] |
| | | |
| <br /> | | <br /> |